Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Current Leases (2020 - 2022)

Updated

Grace Therapeutics (GRCE) reported Current Leases of $430,000 for fiscal Q3 2023 (quarter ended Dec 31, 2022), down 4.4% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Current Leases (2020 - 2022) Analysis & Trends

At the end of FY2022 (ended Mar 31, 2022), Grace Therapeutics posted Current Leases of $191,000.

  • By fiscal year, Current Leases came in at $71,000 in FY2020.
  • Five-year quarterly Current Leases spans a low of $38,000 in fiscal Q2 2021 and a high of $450,000 in fiscal Q2 2023.
  • Per Business Quant data, the three fiscal quarters before Q3 2023 came in at $450,000 (Q2 2023), $174,000 (Q1 2023) and $191,000 (Q4 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn -
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn -
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn -
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn -
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn -
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn -
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn -
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn -
10 Grace Therapeutics 35.10 Mn -35.61 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 430,000.00
Sep 30, 2022 450,000.00
Jun 30, 2022 174,000.00
Mar 31, 2022 191,000.00
Sep 30, 2020 38,000.00
Jun 30, 2020 56,000.00
Mar 31, 2020 71,000.00
API Access

Grace Therapeutics Current Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-leases&ticker=GRCE&period=max&api_key=YOUR_API_KEY